The deal is considered to be a step in the right direction towards preparing the United States for the event of a major influenza pandemic. The licensing agreement grants Emergent BioSolutions, Inc., the right to manufacture and sell VaxInnate’s pandemic flu vaccine in the United States. VaxInnate, in turn, will receive payments and royalties associated with vaccine’s production and sale.
Emergent BioSolutions, Inc., plans to produce the vaccine under a contract signed with the U.S. Biomedical Advanced Research and Development Authority, which operates under the U.S. Department of Health and Human Services. The biopharmaceutical has been designated a Center for Innovation in Advanced Development and Manufacturing.
“Past flu pandemics underscored the need for new vaccines that can be produced rapidly and in large quantities in order to protect the American people,” Wayne Pisano, VaxInnate’s president and CEO, said. “This agreement combines the innovative flu vaccine being developed by VaxInnate with the manufacturing expertise of Emergent.
“We’re pleased to expand our partnership with BARDA and to begin a new one with Emergent. Together we can make significant progress in preparing the U.S. for the next pandemic flu.”
VaxInnate currently holds a contract with BARDA worth up to $196 million over the next five years that funds the company’s use of recombinant technology. Vaccines produced with the technology can be made twice as fast as with conventional methods, making them valuable to use against a pandemic influenza strain.